Monitor for definitive agreement, shareholder vote date, and NYSE American approval. The stock may trade on deal progress and clinical updates for ONP-002. Given the non-binding nature and historical volatility, position sizing should account for binary risk.
Price Chart
Executive Summary
Oragenics signed a non-binding Letter of Intent to license CardioDialysis, an extracorporeal blood purification technology, from Sigyn Therapeutics for TBI and neurodegenerative diseases. The deal includes issuing 3.25M convertible preferred shares (1:1 to common) and a 3% royalty on future sales, but remains subject to due diligence, board approvals, and NYSE American listing compliance. With no FDA-approved treatments for mTBI, the platform strategy is promising but early-stage and contingent on many closing conditions.
Key Facts
- Oragenics signed a LOI to license CardioDialysis from Sigyn Therapeutics for TBI and neurodegenerative disorders.
- Consideration: 3,250,000 shares of a new class of restricted preferred stock, convertible 1:1 to common, subject to shareholder and exchange approvals.
- Oragenics would pay a 3% royalty on sales for six years after first commercial sale per indication/country.
- Target closing within 90 days; LOI is non-binding except for exclusivity, confidentiality, and governing law provisions.
- The license would complement Oragenics' Phase IIa intranasal neurosteroid ONP-002 for mTBI, creating a dual-modality approach to TBI inflammation.
- There are currently no FDA-approved pharmacological treatments for concussion or mTBI; 69 million people worldwide suffer brain injury annually.
Financial Impact
3.25 million shares of convertible preferred stock as consideration; 3% royalty on future net sales (no current revenue or sales projections provided).
Risk Factors
- Definitive agreement may not be executed; due diligence or board approvals could fail.
- Shareholder approval and NYSE American continued listing conditions may not be met.
- Significant dilution from 3.25M convertible shares relative to current market cap ($3M).
- No clinical or commercial data for CardioDialysis in TBI; regulatory pathway uncertain.
- Historical stock performance shows high volatility with negative average returns on prior filings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021627 |
| Exhibit: ex99-1.htm | 0001493152-26-021627 |
| Document: 0001493152-26-021627-index-headers.html | 0001493152-26-021627 |
| Document: 0001493152-26-021627-index.html | 0001493152-26-021627 |
| Document: 0001493152-26-021627.txt | 0001493152-26-021627 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 5w ago | 8-K | $0.5000 $0.4469 | ▼ −10.62% | ▼ −13.80% | $0.3660 (−26.80%) |
Aug 28, 2026 8w ago | 8-K | $0.5098 $0.4800 | ▲ +5.85% | ▲ +5.66% | $0.3660 (+28.21%) |
May 20, 2026 22w ago | DEFA14A | $0.5900 $0.5882 | ▼ −0.31% | ▼ −0.64% | $0.3660 (−37.97%) |
May 19, 2026 23w ago | 8-K | $0.5700 $0.6100 | ▲ +7.02% | ▲ +6.03% | $0.3660 (−35.79%) |
May 7, 2026 24w ago | 8-K | $0.6100 $0.6100 | · 0.00% | ▼ −3.14% | $0.3660 (−40.00%) |
Apr 13, 2026 28w ago | 8-K | $0.6800 $0.5600 | ▼ −17.65% | ▼ −25.38% | $0.3660 (−46.18%) |
Mar 25, 2026 30w ago | Press Release | $0.5800 $0.6400 | ▼ −10.34% | ▲ +0.32% | $0.3660 (+36.90%) |
Mar 23, 2026 31w ago | EFFECT | $0.6800 $0.6600 | ▼ −2.94% | ▼ −10.36% | $0.3660 (−46.18%) |
Mar 11, 2026 32w ago | 8-K | $0.9600 $0.6000 | ▼ −37.50% | ▼ −39.48% | $0.3660 (−61.88%) |
Mar 11, 2026 32w ago | Press Release | $0.8800 $0.6200 | ▼ −29.55% | ▼ −30.07% | $0.3660 (−58.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers